GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation
Open accessThe DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Abstract
Liraglutide and exenatide are glucagon-like peptide receptor (GLP-1R) agonists used in the treatment of type 2 diabetes. Both molecules have been associated with the development of thyroid C-cell tumors after lifetime exposure in rodents. Previously, it has been reported that these tumors are preceded by increased plasma calcitonin and C-cell hyperplasia. We can now document that the murine C-cell effects are mediated via GLP-1R. Thus, 13 wk of continuous exposure to GLP-1R agonists was associated with marked increases in plasma calcitonin and in the incidence of C-cell hyperplasia in wild-type mice. In contrast, similar effects were not seen in GLP-1R knockout mice. Human C-cell cancer is often caused by activating mutations in the rearranged-during-transfection (RET) protooncogene. We developed an immunohistochemical method to assess RET activation in tissues. Liraglutide dosing to mice was not found to activate RET. Further evaluation of the signaling pathways demonstrated that liraglutide increased ribosomal S6, but not MAPK kinase, phosphorylation. These observations are consistent with effects of GLP-1R agonists on rodent C cells being mediated via mammalian target of rapamycin activation in a RET- and MAPK-independent manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pharmacological studies in rodents support an association between the use of GLP-1 RAs and the development of medullary thyroid cancer (MTC) resulting in a black box warning for these agents in patients at risk for this condition.”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [45]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
Daub, H., Ulrich Weiss, F., Wallasch, C., & Ullrich, A. (1996) · Nature · doi:10.1038/379557a0 · Cited by 1,476
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,241
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 10×
“Two of these slides were stained by standard techniques with hematoxylin and eosin and immunohistochemistry (IHC) for calcitonin (7) and used for the histopathological diagnosis.”
BackgroundMethodResultInfluentialSelf-citationBuse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565
International Union of Pharmacology. XXXV. The Glucagon Receptor Family
Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., & Drucker, D. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.6 · Cited by 506
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 1×
“In situ ligand binding We carried out ISLB on tissue sections as previously reported (7, 23).”
MethodThyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992–2006
Aschebrook-Kilfoy, B., Ward, M. H., Sabra, M. M., & Devesa, S. S. (2011) · Thyroid · doi:10.1089/thy.2010.0021 · Cited by 454
Anatomy and embryology of the laboratory rat
Hebel, R., & Stromberg, M. W. (1986) · Cited by 440
Long-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Research works printed but not linked: 3
- DeLellis, 1994, Changes in structure and function of thyroid C-cell, 285
- Botts, 1991, Proliferative lesions of the thyroid and parathyroid glands, E-3, 1
- Boorman, 1996, C-cell hyperplasia, C-cell adenoma, and C-cell carcinoma, thyroid in rats, 262
Cited by
Items 101–161 of 161
Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes
Bloomgarden, Z. T., Blonde, L., Garber, A. J., & Wysham, C. (2012) · Endocrine Practice · doi:10.4158/ep12300.ra · Cited by 7
Impaired glucose metabolism treatment and carcinogenesis
Matyszewski, A., Czarnecka, A. M., Kawecki, M., KORZEŃ, P., SAFIR, I. J., Kukwa, W., & Szczylik, C. A. (2015) · Oncology Letters · doi:10.3892/ol.2015.3324 · Cited by 7
“By contrast, drugs that act via increasing endogenous insulin concentrations, in addition to exogenous insulin itself, may increase the cancer risk (7-9,12,13,32-44).”
Kannan, S., & Nasr, C. E. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13066 · Cited by 8
Albini, A., Cantelmo, A. R., Mortara, L., Noonan, D. M., & Corso, G. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.07.008 · Cited by 8
Ismail, A., Amer, M. S., & Tawheed, A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.107148 · Cited by 7
“Also, exenatide and liraglutide were associated with stimulation of calcitonin release[157,158].”
GLP-1 and GIP: Magic bullet for musculoskeletal diseases?
Fang, Q., Gan, L., Liu, P., Ding, P., & Gao, Y. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.046 · Cited by 6
“Previously, it was thought that GLP-1 could only regulate bone resorption indirectly by binding to rodent thyroid C cells and stimulating CT secretion [53,54].”
Epigenetic regulation in type II diabetes: linking molecular mechanisms to clinical management
Chaudhry, M., & Sif, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01831-1 · Cited by 7
“However, these findings have not been replicated in human clinical trials and epidemiological studies, and current evi - dence does not support a causal relationship in humans [136].”
Effect of GLP-1 Receptor Agonists on Patients with Thyroid Carcinomas Undergoing Active Surveillance
Patrizio, A., Newman, S. K., Tuttle, R. M., & Boucai, L. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf182 · Cited by 7
Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer
Patrizio, A., Mauguen, A., Fagin, J. A., Farooki, A., Fish, S. A., Flory, J., Newman, S. K., Presswala, L. S., Sabra, M. M., Tuttle, R. M., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag051 · Cited by 5
Self-citationSemaglutide in Cardiometabolic Diseases: SELECTing the Target Population
Natale, F., Luisi, E., Franzese, R., Mollo, N., Solimene, A., Caso, V. M., Corvino, A., Golino, P., & Cimmino, G. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050145 · Cited by 8
“A study conducted on rats and mice over a 2-year period showed that semaglutide administration “at clinically relevant exposures” is associated with thyroid C-cell tumors [31].”
BackgroundInfluentialDayel, F. F. B., Alanazi, R. J., Alenazi, M. A., Alkhalifah, S., Alfaifi, M., Alghadeer, S. M., & Alwhaibi, A. M. (2025) · Healthcare · doi:10.3390/healthcare13151827 · Cited by 4
“…that semaglutide and other GLP-1 RAs cause a dose-dependent and treatment-duration-dependent increase in thyroid C-cell hyperplasia, adenomas, and medullary thyroid carcinoma (MTC) in rats and mice, which is mediated by the GLP-1 receptors that are abundantly expressed on rodent C-cells [17].”
Banji, D., Alshahrani, S., Alfarhan, M., & Banji, O. J. F. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00050-2 · Cited by 4
“Emerging data from a few human studies have also found an association between GLP-1 receptor agonists and thyroid malignancies (Madsen et al. 2012).”
Saugstad, A. A., Petry, N., & Hajek, C. A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.857120 · Cited by 3
“Though studies document a GLP-1 receptor dependent role in C-cell hyperplasia and no association with RET activation, the FDA label remains (Madsen et al., 2012).”
ResultGLP-1 Receptor Agonists: Beyond Diabetes—What the Neurosurgeon Needs to Know
Abdulrazeq, H., Taman, M., Ali, R., Doberstein, C., Sullivan, P. Z., Sampath, P., Telfeian, A. E., Gokaslan, Z. L., Fridley, J., & Asaad, W. F. (2024) · Neurosurgery Open · doi:10.1227/neuprac.0000000000000098 · Cited by 7
The Use of Genetically Modified Animals in Discovery Toxicology
Diaz, D., & Maher, J. M. (2016) · Wiley eBooks · doi:10.1002/9781119053248.ch19 · Cited by 3
Glasgow, K., Jiminez, V. S., Garcia, N., & Gillis, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33420 · Cited by 3
“Although calcitonin screening is not required nor recommended in all individuals before starting a GLP-1 agonist outside of a clinical trial, in the case of this patient, it aided in early identification of MTC and familial MEN 2 [14].”
BackgroundWatts, E., Wadsley, J., Sharma, N., Boelaert, K., & The UK Thyroid Cancer Study Group (2025) · Clinical Endocrinology · doi:10.1111/cen.70084 · Cited by 7
Song, E., Fang, Y., Li, X., Fu, W., He, H., Gao, Z., Tian, X., & Gao, B. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1809416 · Cited by 3
Haddadin, J., Haddad, A., Nahar, L., Hamarneh, O., & Haddad, F. (2026) · HORMONES · doi:10.1007/s42000-026-00801-3 · Cited by 2
Narrative Review of Perioperative Glucagon-like Peptide-1 (GLP-1) Agonists in Spine Surgery
Connelly, J. W., Narayanan, R., Ezeonu, T., Kothari, P., Spina, N., Spiker, W. R., Lawrence, B. D., Brodke, D. S., Schroeder, G. D., & Karamian, B. A. (2025) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001888 · Cited by 2
The effects of incretins as a double-edged sword on cancer
Mavaddat, H., Fouladi, A., Peyrovinasab, A., Khayatan, I., Targhi, H. J., Fakhri, M., Andarzbakhsh, K., Büsselberg, D., Razavi, S. M., & Rezazadeh, A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11062-5 · Cited by 2
Gopinath, C., & Mowat, V. (2014) · Humana Press eBooks · doi:10.1007/978-1-62703-998-7_8 · Cited by 2
Exenatide Once Weekly: Opportunities in the Primary Care Setting
Davidson, J. A., Nikkei, C., & Grimm, M. F. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2662 · Cited by 2
One feature doesn't fit all: characterizing topological features of targets in signaling networks
Chua, H. E., Bhowmick, S. S., & Tucker‐Kellogg, L. (2014) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/2649387.2649424 · Cited by 3
“Dulaglutide [LY2189265] [286] 01769378, 01644500, 01584232, 01648582, 01624259, 01621178, 01394952, 01667900, 01432938, 01436201, 01524770, 01468181, 01408888, 01064687, 00630825, 01558271, 01075282, 00734474, 01126580, 01191268, 01301092, 00791479, 01001104, 01324388, 01300260 activated GLP-1 receptor GLP-1R agonist”
Makunts, T., Joulfayan, H., & Abagyan, R. (2023) · PubMed Central · doi:10.1101/2023.11.19.23298750 · Cited by 3
Glucagon-like Peptide 1 Receptor Agonists Do Not Alter Calcitonin Levels in Humans
Toft, D. J. (2019) · Clinical Thyroidology · doi:10.1089/ct.2019;31.253-255 · Cited by 1
“Activating mutations in the RET proto-oncogene pathway drive the majority of medullary thyroid carcinomas (MTCs) in humans, while GLP1-stimulated calcitonin secretion in rodents has been shown to be independent of RET activation (2,3).”
The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care
Mazza, A. D. (2025) · Cureus · doi:10.7759/cureus.98153 · Cited by 4
“These findings are attributed to GLP-1 receptor expression in rodent thyroid C cells, which differs significantly from humans, where receptor expression is sparse and inconsistent [48,61].”
Sciscent, B. Y., Eberly, H. W., Lorenz, F. J., Goldrich, D. Y., Goyal, N., & Goldenberg, D. (2026) · OTO Open · doi:10.1002/oto2.70188 · Cited by 2
“6,25 However, this may be due to differences in species expression of GLP ‐ 1 receptors.”
Shah, P. P., & Bhattacharya, R. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101418 · Cited by 2
“Here it is crucial to clarify: this specific thyroid tumor was seen in rats and mice given extremely high doses of GLP-1RAs over their life-spans, but it has never been observed in humans on these medications [41 – 43].”
Mixed Medullary and Papillary Thyroid Carcinoma in a Patient on Tirzepatide
Beshay, L. H., Makker, J., & Ahern, S. (2026) · Cureus · doi:10.7759/cureus.107836 · Cited by 2
Short-term effect of tirzepatide on serum calcitonin in adults with obesity
Angelopoulos, N., Simeakis, G., Androulakis, I., Rizoulis, A. A., Boniakos, A., Mentzelopoulou, P., Korakovouni, A., Zianni, D., Petkova, V., Livadas, S., et al. (2026) · Endocrine · doi:10.1007/s12020-026-04655-y · Cited by 1
Hung, C., Yen, F., Huang, J.-Y., & Wei, J. C. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.05.010 · Cited by 1
Kennedy, S., Thomas, J., Darcy, S., Odia, I., Kamdar, D., Pereira, L., Scarola, D., Miles, B., Frank, D. K., Taneja, C., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1834606 · Cited by 1
“This warning is based on a dose-dependent rodent trial that found that mice exposed to supraphysiologic doses of GLP-1 RAs were more likely to experience C-cell hyperplasia (12, 13).”
InfluentialThe association between genetically proxied GLP-1 receptor agonists and cancer risks
Zhou, F., Yang, Z., Xing, M., Zong, G., Feng, C., Wang, J., & Geng, X. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005253 · Cited by 1
“Supporting these observations, a rodent study reported that continuous exposure to GLP-1R agonists led to elevated plasma calcitonin levels and a higher incidence of thyroid C-cell hyperplasia in wild-type mice [ 14 ] .”
Hundal, J., Linz, M. O., Anikreddy, S., Sengupta, S., Zhou, K., & Maiti, B. (2026) · JCO Oncology Practice · doi:10.1200/op-26-00061 · Cited by 1
Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review
van Maren, S., van Doorn, E. P. M., Smits, M. M., Tack, C. J., van Rossum, E. F. C., & Messaoudi, S. E. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02073-3 · Cited by 1
“A large concern was raised when several pre-clinical studies suggested a possible association between the use of GLP-1RAs and an increased risk of thyroid C-cell tumours [52].”
Kawkgi, O. M. E. (2025) · Clinical Thyroidology · doi:10.1089/ct.2025;37.33-36 · Cited by 1
Zhong, Y., Dambach, D. M., & Maher, J. M. (2018) · Veterinary Pathology · doi:10.1177/0300985817747328 · Cited by 1
Hart, N. J. (2013) · UA Campus Repository (The University of Arizona)
Taşkıran, B., & Cansu, G. B. (2017) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.308303
“PTK vakalarında GLP-1 pozitifliğinin saptanması, normal tiroid folikül hücrelerinde sunulmasa da aberan olarak PTK hücrelerinde GLP-1 sunulabileceğini akla getirmiştir (2,3,10).”
BackgroundAnti-Obesity Pharmacotherapy After Bariatric Surgery
Saunders, K. H. (2018) · Springer eBooks · doi:10.1007/978-3-030-01039-3_14
Effect of Obestatin on Bone Turnover in Normal and Obese Male Albino Rats
KHALIL, M. D. R. H. I. S. S. (2019) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2019.52355
A brief review on newer Glucagon like Peptide-1 analogues
Dharmaraj, B. (2020) · International Journal of Preclinical and Clinical Research · doi:10.51131/ijpccr/v1i1.7
“(32) More data are required to provide reassurance about current safety concerns surrounding this class of therapies”
BackgroundGLP-1-Analoga: Was ist in der Praxis zu beachten?
Ritzel, R. A. (2020) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-020-0390-2
Chang, L., & Kim, M. I. (2016) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2016.05.004
Bonnet, J., Durieux, A. T., Tournayre, S., Marty, L., Sultan, A., & Avignon, A. (2024) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2024.03.009
Glucagon-like Peptide-1 Receptor Agonists and Gastrointestinal Neoplasms
Kim, Y. J., & Bae, J. (2025) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2025.13.2.99
A systematic review of transgender male rodent model methodology
Robertson, K., Lane, D., Donner, D. G., Peart, J. N., & Toit, E. D. (2025) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70088 · Cited by 1
Anti-obesity Pharmacotherapy for Transplant Recipients
Haugen, C. E., & Orandi, B. J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01388-1 · Cited by 1
Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists
Rashid, Z., Woldesenbet, S., Khalil, M., Altaf, A., Zindani, S., Mevawalla, A., Sarfraz, A., Mumtaz, K., & Pawlik, T. M. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10300-1 · Cited by 1
Porter, M. W., Ghorbani, T., & Cubb, T. D. (2026) · Clinical Thyroidology · doi:10.1177/23299711261441003
Hsieh, H., Huang, Y., Chang, Y.-W., & Liao, W. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261460619
From promise to prudence: Integrating semaglutide into Indian clinical practice
Patel, A. B., Patel, V., & Modi, U. (2026) · Indian Journal of Physiology and Pharmacology · doi:10.25259/ijpp_723_2025
Repurposing metabolic drugs: Anti-diabetic and anti-obesity agents with potential in cancer therapy
Uti, D. E., Almohaimeed, H. M., Aggad, W. S., Egbung, J. E., Anthony, B. O., Ogar, R. O., & Alum, E. U. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100747
Roach, K. A., Khazaee, M., Mohar, I., Boon, D., Cronin, B., & Gauthier, A. G. (2026) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2026.106252
Li, B., Liu, L., Luo, E., Liu, H., & Rosen, C. J. (2026) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2026.102208
Insights from multi-omics on GLP-1 receptor agonists in type 2 diabetes and obesity
Elashi, A. A., Hedaya, L., Maggio, V., Naja, K., Rizzo, M., & Elrayess, M. A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1812193
“In rodents, Liraglutide induced dose-and treatment-duration-dependent thyroid C-cell tumors (Madsen et al., 2012).”
Thyroid Disease in the Era of Obesity and Glucagon-Like-Peptide-1 Agonists
Coblens, O. M., Dunmire, A. M., & Maldonado-Chapa, F. (2026) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2026.06.002
GLP-1 Receptor Agonist Therapy in Patients with Cancer: A Review of Clinical Outcomes
Andronescu, A.-C., Ciumărnean, L., Orasan, O. H., Cozma, A., Leah, N. V., Lucaciu, R. L., Hangan, A. C., & Procopciuc, L. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209251
“Early safety concerns were based on rodent studies reporting thyroid C-cell hyperplasia following long-term liraglutide exposure [14].”
InfluentialGLP-1 RECEPTOR AGONISTS AND THYROID DISEASE: FROM MECHANISM TO CLINICAL PRACTICE
Milewska, A., Bociąg, A., Kowalski, K., Marciniak, R., & Ptach, Ł. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(52).2026.6324
Al-Mashhadani, M. M., Khalifa, A., Al-Mashhadani, Y., Ajaz, F., Barragán, C., & Alsaeed, M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113630
Metadata
- Authors
- Madsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., Vundavalli, S., Nyborg, N. C. B., Bjerre Knudsen, L., Moelck, A. M., & Fagin, J. A.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Memorial Sloan Kettering Cancer Center (US)
- Huntingdon Life Sciences (A.P.), Eye, Suffolk, IP23 7PX, United Kingdom
- Novo Nordisk A/S (L.W.M., C.G., I.S., S.A., L.A., A.S.d.B., N.C.B.N., L.B.K., A.M.M.), Novo Allé, DK-2880, Bagsvaerd, Denmark
- Memorial Sloan-Kettering Cancer Center (J.A.K., K.M., A.B., S.V., J.A.F.), New York, New York 10065
- Corresponding author
- Madsen, Lars Wichmann
- Fagin, James A.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2012-03-01
- Volume
- 153
- Issue
- 3
- Pages
- 1538-1547
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC3281535
- OpenAlex
- W2166969890
- Cited by
- 161
- References
- 29
- Citations by year
- 2026: 27 · 2025: 24 · 2024: 15 · 2023: 5 · 2022: 4 · 2021: 2 · 2020: 12 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 8 · 2015: 11 · 2014: 11 · 2013: 15 · 2012: 6
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrinology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA-72597, R01CA072597)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- GLP-1 receptor agonists, liraglutide, exenatide, RET proto-oncogene, calcitonin, mTOR signaling, type 2 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Calcitonin, Female, Immunohistochemistry, Ligands, Male, Models, Genetic, Phosphoproteins, Thyroid Gland, Time Factors, Signal Transduction, Receptors, Glucagon, Mice, Knockout, Proto-Oncogene Proteins c-ret, Mice, Glucagon-Like Peptide 1, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.